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Abstract
We reported macrolipasemia in a colon cancer patient during the chemotherapy period without any evidence of pancreatitis. A 52-year-old man 
formerly treated for papillary thyroid carcinoma had elevated a carcinoembryonic antigen (CEA) concentration in the latest control and was diagno-
sed with colon cancer. Xelox chemotherapy (oxaliplatin and capecitabine) protocol was planned for six months. Interestingly, the lipase activities 
gradually increased from 30 U/L to 434 U/L, and exceeded three times the upper limit of the reference range (13-60 U/L). There were no symptoms 
of pancreatitis, and the abdominal computed tomography (CT) scan was also normal. Polyethylene glycol (PEG) recovery % values of serum samples 
gradually decreased and were 27% in the recent sample before the end of chemotherapy. Interestingly, the serum lipase activity fell a month after 
chemotherapy, and PEG recovery % increased (39%). We considered the following possibilities: (1) macrolipasemia due to chemotherapy drugs, (2) 
macrolipasemia due to antibodies against chemotherapy drugs.
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Introduction
Elevated serum amylase and lipase activities are 
important in the diagnosis of pancreatitis. A high 
amylase is not specific to pancreas disease and 
may be associated with other clinical conditions. 
Increased lipase activity associated with patients’ 
clinical symptoms is a more reliable and specific 
test for pancreatic disease (1,2). However, lipase el-
evation due to macrolipasemia is an extremely 
rare condition, such that there have been very few 
reports of macrolipasemia in the literature.
Macroenzymes are high molecular weight forms 
of plasma enzymes occurred by self-polymeriza-
tion or binding to other plasma components, can-
not be excreted by the kidneys, and cause in-
creased enzyme activities. They are divided into 
two groups. It is known that immunoglobulins 
form complexes with various plasma enzymes. Im-
munoglobulin complexed enzymes are Type 1 
macroenzymes. Type 2 macroenzymes are en-
zymes complexed with non-immunoglobulin 
plasma components (for example, lipoproteins, 
xenobiotics) or made by self-polymerization. One 
of these components may also be foreign sub-
stances (for example, drugs) (3,4).  
Macroenzymes are suspected in atypical clinical 
cases associated with high serum enzyme concen-
trations (5). Macroenzymes must be detected as 
they may cause false high serum enzyme results 
and, therefore, diagnostic and therapeutic errors 
(4).
Unlike the literature, we reported macrolipasemia 
in a colon cancer patient during the chemothera-
py period without any evidence of pancreatitis.
Case
In the latest control, a 52-year-old man formerly 
treated for papillary thyroid carcinoma had elevat-
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ed a carcinoembryonic antigen (CEA) concentra-
tion. Measured CEA value was 12 µg/L (reference 
range: 0-6.5 µg/L). Furthermore, a lesion was de-
tected by colonoscopy. The patient was operated 
on and diagnosed with Stage 3 (T3/N1/M0) colon 
cancer. Xelox chemotherapy (oxaliplatin and 
capecitabine) protocol was planned for six 
months. Routine biochemical tests were followed 
during chemotherapy. Interestingly, the lipase ac-
tivities gradually increased and exceeded three 
times the upper limit of the reference range (13-60 
U/L). Almost all simultaneously measured amylase 
activities were in the reference range (28-100 U/L) 
(Figure 1). The patient had not previously been on 
drugs other than 150 µg of levotiron, cigarettes, 
and alcohol. There were no symptoms of pancrea-
titis (abdominal pain, nausea, vomiting, and fever), 
and the abdominal computed tomography (CT) 
scan was also normal. We suspected macrolipa-
semia in the patient without clinical and radiologi-
cal signs of pancreatitis. The patient signed an in-
formed consent form for anonymous publication 
of medical data.
Methods
The blood samples taken into serum separator 
tubes (Vacuette, Greiner Bio-One GmbH, Krems-
münster, Austria) were centrifuged at 2000xg for 
10 minutes, and serum samples were separated. 
Fresh serum samples’ amylase and lipase activities 
were performed on Cobas c701 (Roche Diagnos-
tics, Mannheim, Germany) with original Roche test 
kits and enzymatic colorimetric methods. The li-
pase activity in the serum sample taken on Sep-
tember 25, 2020 was additionally evaluated on Ar-
chitect c16000 (Abbott Diagnostics, Massachu-
setts, United States) with original Abbott test kits 
and enzymatic colorimetric methods to exclude 
analytical errors.
Lipase activities were measured after polyethylene 
glycol (PEG) (PEG 6000, CAS-No: 25322-68-3, Mer-
ck KGaA, Darmstadt, Germany) precipitation to 
evaluate macrolipasemia. After mixing 200 µL of 
serum and 200 µL of 25% PEG, mixture was incu-
bated at room temperature for 10 minutes. Then it 
was centrifuged at 13000xg for five minutes. Li-
pase activity was determined in the supernatant, 
and PEG recovery % was calculated according to 
the following formula:
PEG recovery % = (Post-PEG lipase activity / Pre-
PEG lipase activity) x 100.
In addition, Immunoglobulin (Ig)G, IgA, IgM, total 
kappa, and total lambda concentrations in the 
blood sample taken on September 25, 2020 were 
evaluated on Cobas e801 (Roche Diagnostics, 
Mannheim, Germany) with original Roche test kits 
and electrochemiluminescence immunoassay 
(ECLIA) methods. 
Figure 1. Changes in serum amylase and lipase activities in a patient. The patient received his first treatment on June 26, 2020 (left 
vertical line) and the last on December 15, 2020 (right vertical line). After the first treatment, lipase values increased rapidly. The ac-












21.05.2020 26.06.2020 23.07.2020 13.08.2020 25.09.2020 9.11.20206.07.2020 3.09.2020 16.10.2020 15.01.2021
Lipase (U/L)
Amylase (U/L)
17 30 56,5 52 84 207 327 434 330 123
30,2 32 56,8 50 60 83 98 105 94 66
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Results
PEG recovery % values of serum samples gradually 
decreased and were 27% in the recent sample be-
fore the end of chemotherapy. However, a month 
after chemotherapy, the serum lipase activity de-
creased (123 U/L), and PEG recovery % increased 
(39%) (Table 1).
The lipase activities in the same serum sample 
(September 25, 2020) were measured as 327 U/L 
on Roche and 238 U/L on Abbott, and consequent-
ly, the analytical error was excluded.
Serum IgG, A, M, total kappa, and lambda concen-
trations are shown in Table 2. The increased total 
kappa concentration is striking.
25.09.2020 16.10.2020 09.11.2020 15.01.2021
Pre-PEG lipase (U/L) 327 434 330 123
Post-PEG lipase (U/L) 122 128 90 48
PEG recovery 37% 29% 27% 39%
Lipase PEG recovery % values of the patient gradually decreased during chemotherapy and became compatible with 
macrolipasemia (< 32%). A month after the end of chemotherapy (last column), it increased dramatically. PEG - polyethylene glycol.
Test Result Reference Range
IgG 14.83 g/L 7-16
IgA 2.34 g/L 0.7-4.0
IgM 0.907 g/L 0.4-2.3
Total kappa 4.24 g/L ▲ 1.56-4.08
Total lambda 2.01 g/L 0.83-2.24
Table 1. Changes in PEG recovery % of lipase
Table 2. Immunoglobulin (Ig)G, IgA, IgM, total kappa and total 
lambda concentrations on September 25, 2020.
Discussion
Initially in this case, high lipase activities brought 
to mind acute pancreatitis, but clinical and radio-
logical evidence was not present. The persistence 
of lipase elevation, absence of concomitant amyl-
ase elevation, and clinical incompatibility with 
pancreatitis suggested macrolipasemia.
There were no inconsistencies in the current auto-
analyser’s internal and external quality control 
data (Roche), and we also detected high lipase ac-
tivity on an alternative autoanalyser (Abbott). 
Therefore, we excluded the analytical error. 
The PEG recovery % reference range for lipase is 
reported as 32–75%. Recovery % values lower than 
32% are in favour of macrolipasemia (6). In this 
case, we found that lipase PEG recovery % values 
were 29% and 27% (< 32%) during the chemother-
apy process. These findings supported that the el-
evated lipase activity in the patient were due to 
macrolipasemia.
Previously, macrolipasemia has been reported in 
autoimmune diseases, inflammatory diseases, and 
lymphoma (7-10). For the first time, we reported 
macrolipasemia secondary to colon cancer chem-
otherapy. 
Different tumour types have been shown to ex-
press lipase, and there are reported cases of tu-
mor-derived lipase-related lipase elevation (11-13). 
It has been shown that lipase activities rapidly de-
crease after treatment (13). In this case, on the con-
trary, lipase activities increased after chemothera-
py. Therefore, we did not consider tumor-derived 
lipase-related lipase elevation.
In the literature, there are previously reported few 
cases of oxaliplatin and capecitabine-induced 
pancreatitis. Clinical, laboratory and radiological 
evidence of acute pancreatitis is available in all 
those cases (14,15). 
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It is known that enzymes can transform to the 
macroenzyme by forming a drug complex (3). 
Since lipase activities gradually increase during 
chemotherapy and decrease after the end of 
chemotherapy (PEG recovery % values are the op-
posite of these), we considered the following pos-
sibilities in this patient: (1) macrolipasemia due to 
lipase complexation with one or both of the chem-
otherapy drugs (oxaliplatin and capecitabine); (2) 
macrolipasemia due to lipase complexation with 
advanced antibodies against one or both chemo-
therapy drugs. The elimination half-life of oxalipl-
atin is 12-50 days, and the elimination half-life of 
capecitabine is approximately 30-50 minutes 
(16,17). The return of macrolipasemia a month af-
ter chemotherapy suggests that it may be mainly 
related to oxaliplatin. 
Besides, the high value of total kappa suggests an-
tibody-related macrolipasemia. There are report-
ed cases of macroenzymes complexed with kappa 
in the literature (18). 
During chemotherapy, the development of pan-
creatitis is an indication to stop treatment. There-
fore, it is essential to reveal the presence of mac-
rolipasemia in this group of patients.
In conclusion, in patients receiving chemotherapy, 
it should be kept in mind that drugs may trigger 
macroenzyme formation (drug and/or antibodies 
against drug) and cause enzyme elevations incom-
patible with the patients’ clinical condition.
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